Sum and substance in the Jikei Heart Study

Lancet

Volumn 369, Issue 9571, 2007, Pages 1407-1408

  Staessen, Jan A ^a   Richart, Tom ^a  

^a Hypertension and Cardiovascular Rehabilitation Unit   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; PRIORITY JOURNAL; STANDARDIZATION; TREATMENT OUTCOME;

EID: 34247402881     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60643-6     Document Type: Note

References (14)

1. Mochizuki S., Dahlöf B., Shimizu M., and for the JIKEI Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 (2007) 1431-1439
2. Dahlöf B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
3. Staessen J., Wang J., and Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet 358 (2001) 1305-1315
4. Verdecchia P., Reboldi G., Angeli A., et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46 (2005) 386-392
5. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
6. Hansson L., Hedner T., and Dahlöf B. Prospective randomized open blinded end-point (PROBE) study: a novel design for intervention trials. Blood Press 1 (1992) 113-119
7. Zhang H., Thijs L., and Staessen J. Blood pressure lowering for the primary and secondary prevention of stroke. Hypertension 48 (2006) 187-195
8. Staessen J., Thijs L., Fagard R., et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 22 (2004) 847-857
9. Julius S., Kjeldsen S., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet 363 (2004) 2022-2031
10. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
11. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25 (2007) 951-958
12. Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004) (2004), Japanese Hypertension Society, Tokyo
13. Maillard M., Würzner G., Nussberger J., Centeno C., Burnier M., and Brunner H. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 71 (2002) 68-76
14. Casas J., Chua W., Loukogoergakis S., et al. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic reveiw and meta-analysis. Lancet 366 (2005) 2026-2033